ClinicalTrials.gg
CompletedNCT04987203Updated May 8, 2026

Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

A Phase 3 interventional study of Tivozanib and Nivolumab in Renal Cell Carcinoma, sponsored by AVEO Pharmaceuticals, Inc.. Completed at 139 sites in 16 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by AVEO Pharmaceuticals, Inc. (part of LG Chem) · Phase 3, Interventional, and Treatment

How we know · 7 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
343
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies testing tivozanib in Carcinoma, Renal Cell — 1 open to participants now, 2 under way, 1 of them phase 3. tivozanib · Carcinoma, Renal Cell.

Enrollment
4th of 13
343 · median 105
Started
2021
the only one that year
Phase 3
5 of 13
1 open now
Registered
11th of 13
by date
Lead sponsor
9 of 13
AVEO Pharmaceuticals, Inc.

Among the 13 studies testing tivozanib in Carcinoma, Renal Cell, this one is the 4th largest by enrollment, is the only one that started in 2021, is one of 5 in phase 3, and was the 11th registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

1 of the 13 studies testing tivozanib in Carcinoma, Renal Cell is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About tivozanib

tivozanib: first FDA approval 2021 (FOTIVDA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing tivozanib in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

This study will be comparing tivozanib in combination with nivolumab to tivozanib alone in subjects with advanced Renal Cell Carcinoma (RCC) who have had 1 or 2 prior lines of therapy, one of which was an Immune Checkpoint Inhibitor (ICI).

Read the detailed description

This will be an open-label, randomized, controlled, multicenter, multi-national, parallel-arm study. The study is designed to compare the progression free survival (PFS), overall survival (OS), Objective response rate (ORR), duration of response (DoR), and safety of tivozanib and the combination of tivozanib with nivolumab.

Approximately 326 subjects with refractory advanced RCC at approximately 190 sites will be randomized in a 1:1 ratio to treatment with tivozanib plus nivolumab (163 subjects) or tivozanib (163 subjects). Subjects will be randomly assigned to a treatment.

Subjects will receive 1.34 mg/day (monotherapy arm) or 0.89mg/day (combination arm) of tivozanib once daily (QD) for 3 weeks followed by 1 week off study drug. One cycle will be defined as 4 weeks: 3 weeks on treatment and 1 week off treatment. Subjects who receive nivolumab will be infused with 1 treatment of nivolumab at specified dose on specified days of each Cycle.

Subjects with documented stable disease or an objective response may continue to receive both tivozanib and nivolumab therapy at the same dose and schedule until progression as long as the tolerability is acceptable. Nivolumab will be discontinued in all subjects after 2 years; Tivozanib may be continued after discontinuation of nivolumab until other withdrawal criteria are met. A Safety Follow-up Visit will be performed 30 days (± 7 days) after the last dose of study drug.

03

Conditions studied

  • Renal Cell Carcinoma

Keywords

  • Immune Checkpoint Inhibitor
  • Open-label
  • Monotherapy
  • Disease Progression
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Radiographic disease progression during or following at least 6 weeks of treatment with ICI for locally advanced or RCC with a clear cell component either in first- or treatment.
  • Subjects must have recovered from the adverse events of prior therapy to grade ≤ 1 or baseline.
  • or cytologically confirmed RCC with a clear cell component.
  • per criteria Version 1.1.
  • performance status of 0 or 1.
  • All participants must follow protocol defined measures.

Exclusion criteria

Exclusion Criteria:

  • Subjects who received: a. A single agent tyrosine kinase inhibitor (TKI) in the setting followed by a single agent (ICI) in the second line setting; b. More than 2 prior lines of therapy in the advanced or setting.
  • History of life-threatening toxicity related to prior immune therapy.
  • Active disease as well as those that required discontinuation of prior immuno-oncological (IO) therapy due to immune mediated AEs.
  • Uncontrolled hypertension.
  • More than 1 prior line of therapy with a checkpoint inhibitor in the metastatic setting.
  • Subjects on immune suppressive therapy for organ transplant or subjects with a history of genetic or acquired immune suppression disease such as (HIV) [Patients with HIV who have >350 cells/µL, without a history of acquired immune deficiency syndrome (AIDS)-defining opportunistic infections, and are on established antiretroviral therapy which does not include a cytochrome P450 (CYP)3A4 inducer, for at least 4 weeks and have an HIV viral load less than 400 copies/mL, are eligible].
  • History of interstitial lung disease or current non-infectious pneumonitis.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
343 participants (actual)

Study arms

  • Experimental
    Tivozanib in Combination with Nivolumab

    Subjects with advanced RCC will receive 0.89 mg of tivozanib once daily (QD) for 3 weeks followed by 1 week off study drug and nivolumab every 4 weeks on Day 1 of each Cycle, until disease progression or unacceptable toxicities occur, other withdrawal criteria are met, or completion of 2 years of treatment \[for nivolumab\] whichever occurs first.

    Drug: Tivozanib · Drug: Nivolumab

  • Experimental
    Tivozanib

    Subjects with advanced RCC will receive 1.34 mg of tivozanib once daily (QD) for 3 weeks followed by 1 week off study drug until disease progression or unacceptable toxicities occur, or other withdrawal criteria are met.

    Drug: Tivozanib

Interventions

  • Tivozanib will be administered orally.

  • Nivolumab will be administered via intravenous infusion.

06

What researchers measure

Primary outcomes

  1. Progression free survival

    Comparison of the PFS of tivozanib in combination with nivolumab to tivozanib in subjects with RCC who have progressed following 1 or 2 lines of therapy. PFS is defined as the time from randomization to first documentation of objective tumor progression (progressive disease \[PD\], radiological) according to Response Evaluation Criteria In Solid Tumors (RECIST), or death due to any reasons whichever comes first.

    Time frame: Until progressive disease [PD] (Approximately 30 months)

Secondary outcomes

  1. Overall Survival

    Comparsion of the OS of subjects randomized to treatment with tivozanib in combination with nivolumab compared to tivozanib. OS is defined as the time from the date of randomization to date of death due to any cause.

    Time frame: From Screening (Days -28 to -1) until death (Approximately 42 months)

  2. Progression free survival

    PFS is defined as the time from randomization to first documentation of objective tumor progression (progressive disease \[PD\], radiological) according to RECIST, or death due to any reasons whichever comes first. PFS as assessed by investigator.

    Time frame: Until progressive disease [PD] (Approximately 30 months)

  3. Objective Response Rate

    Comparison of ORR of subjects randomized to treatment with tivozanib in combination with nivolumab compared to tivozanib. ORR is defined as the proportion of subjects with confirmed complete response or confirmed partial response according to RECIST relative to the total population of randomized subjects.

    Time frame: From Screening (Days -28 to -1) until PD (Approximately 30 months)

  4. Duration of Response

    Comparison of DoR of subjects randomized to treatment with tivozanib in combination with nivolumab compared to tivozanib. DoR is defined as the time from the first documentation of objective tumor response to the first documentation of objective tumor progression or to death due to any cause.

    Time frame: From Screening (Days -28 to -1) until PD or death (Approximately 30 months)

  5. Number of subjects with serious and non-serious adverse events

    Assessment of the safety and tolerability of tivozanib in combination with nivolumab compared to tivozanib.

    Time frame: From Screening (Day -28 to Day -1) to Follow-up visit (30 days after last dose of study drug ± 7 days)

07

Study locations

139 sites
  • City of Hope Comprehensive Cancer Center
    Duarte, California 91010, United States
  • Chao Family Comprehensive Cancer Center, UC Irvine
    Irvine, California 92868, United States
  • University of California San Diego
    La Jolla, California 92037, United States
  • Leland Stanford Junior University
    Redwood City, California 94063, United States
  • Kaiser Permanente Riverside Medical Center
    Riverside, California 92505, United States
  • US Oncology - Rocky Mountain Cancer Centers - Midtown
    Denver, Colorado 80218-1237, United States
  • Florida Cancer Specialists & Res Inst
    Fort Myers, Florida 33901, United States
  • Florida Cancer Specialists & Research Institute (FCS) - Tampa Cancer Center Location
    St. Petersburg, Florida 33705, United States
  • The University of Kansas Cancer Center
    Westwood, Kansas 66205-2005, United States
  • University of Kentucky UK Markey Cancer Center
    Lexington, Kentucky 40536, United States
  • Tulane Cancer Center Clinic - Oncology
    New Orleans, Louisiana 70112, United States
  • University of Maryland Medical Center-Greenebaum Cancer Ctr
    Baltimore, Maryland 21201, United States
  • John Hopkins Medicine - Hematology/oncology
    Baltimore, Maryland 21287, United States
  • Maryland Oncology Hematology
    Clinton, Maryland 20735, United States
  • Dana-Farber Cancer Institute - Medicine
    Boston, Massachusetts 02215, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • St. Vincent Frontier Cancer Center
    Billings, Montana 59102-6746, United States
  • Oncology Hematology West PC dba Nebraska Cancer Specialists
    Omaha, Nebraska 68130, United States
  • Memorial Sloan Kettering Cancer Center - Monmouth - Oncology
    Middletown, New Jersey 07748-3052, United States
  • University of New Mexico - Comprehensive Cancer Center
    Albuquerque, New Mexico 87131-0001, United States
  • Roswell - Roswell Park Cancer Institute - Medical Oncology
    Buffalo, New York 14263, United States
  • Memorial Sloan Kettering Cancer Center - Westchester
    East White Plains, New York 10604, United States
  • Memorial Sloan Kettering Cancer Center (MSKCC) - Memorial Hospital
    New York, New York 10065, United States
  • Memorial Sloan Kettering Cancer Center - Nassau
    Uniondale, New York 11553, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195-0001, United States
  • Lehigh Valley Physician Group
    Allentown, Pennsylvania 18103-6218, United States
  • Allegheny General Hospital (AGH)
    Pittsburgh, Pennsylvania 15212-4756, United States
  • UH Cleveland Medical Center
    Columbia, South Carolina 29210, United States
  • Chattanooga Oncology and Hematology Associates
    Chattanooga, Tennessee 37404, United States
  • Tennessee Oncology, PLLC
    Nashville, Tennessee 37203, United States
  • Vanderbilt-Ingram Cancer Center
    Nashville, Tennessee 37232, United States
  • Texas Oncology - Central Austin Cancer Center
    Austin, Texas 78731, United States
  • Texas Oncology - Baylor Charles A. Sammons Cancer Center
    Dallas, Texas 75246, United States
  • US Oncology Texas Oncology (CCC of South Texas) - San Antonio Medical Center
    San Antonio, Texas 78240, United States
  • University Of Washington - Medical Center
    Seattle, Washington 98109, United States
  • Northwest Medical Specialties PLLC
    Tacoma, Washington 98405-5016, United States
  • Centro Oncológico Korben
    Buenos Aires, Ciudad Autónoma de Buenos Aire C1280AEB, Argentina
  • Clínica Viedma
    Viedma, Río Negro Province R8500JYJ, Argentina
  • Centro Oncologico de Rosario
    Rosario, Santa Fe Province S2000KZE, Argentina
  • Centro para la Atención Integral del paciente Oncológico
    San Miguel de Tucumán, Tucumán Province T4000GTB, Argentina
  • Liverpool Hospital Cancer Therapy Centre
    Liverpool, New South Wales 2170, Australia
  • Mater Misericordiae Limited
    Brisbane, Queensland 4101, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
  • Sunshine Hospital
    Geelong, Victoria 3220, Australia
  • ZNA Jan Palfijn
    Merksen, Antwerpen 2170, Belgium
  • Institut Jules Bordet - Oncologie Médicale
    Anderlecht, Brussels Capital 1070, Belgium
  • Jessa Ziekenhuis - Campus Virga Jesse - Medische Oncologie
    Hasselt, Limburg 3500, Belgium
  • UZ Gent - Medische Oncologie
    Ghent, Oost-Vlaanderen 9000, Belgium
  • CHU Brugmann - Victor Horta
    Brussels, 1020, Belgium
  • AZ Groeninge - Campus Kennedylaan
    Kortrijk, 8500, Belgium
  • Centro Gaucho Integrado de Onc
    Porto Alegre, Rio Grande do Sul 90110-270, Brazil
  • Clinica de Neoplasias Litoral
    Itajaí, Santa Catarina 88301-220, Brazil
  • Universidade Estadual de Campi
    Campinas, São Paulo 13083-970, Brazil
  • Instituto Brasileiro de Controle do Cancer - ibcc
    São Paulo, São Paulo 03102-002, Brazil
  • Hospital Nossa Senhora da Conc
    Porto Alegre, 90610-000, Brazil
  • Pontificia Universidade
    Porto Alegre, 90610-000, Brazil
  • Tom Baker Cancer Centre
    Calgary, Alberta T2N 4N2, Canada
  • BC Cancer - Vancouver Centre
    Vancouver, British Columbia V5Z 4E6, Canada
  • Sunnybrook Research Institute, sunnybrook Health Sciences Ct
    Toronto, Ontario M4N 3M5, Canada
  • University Health Network - Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
  • Centro de Estudios Clinicos In
    Santiago, Región Metropolitana de Santia 8420383, Chile
  • Centro de Estudios Clínicos SAGA SpA
    Santiago, Región Metropolitana de Santia, Chile
  • Meditek Ltda.
    Santiago, Santiago Metropolitan 8420383, Chile
  • ACEREY Centro de Investigación Clínica Oncológica
    Viña del Mar, Valparaiso 2520612, Chile
  • University Hospital Brno
    Brno, Brno-město 625 00, Czechia
  • Fakultni Thomayerova nemocnice
    Prague, Praha 4 140 59, Czechia
  • FN Hradec Kralove
    Hradec Králové, 500 05, Czechia
  • FN Kralovske Vinohrady
    Prague, 100 34, Czechia
  • Institut de cancérologie de Strasbourg Europe - ICANS
    Strasbourg, Alsace 67200, France
  • Hospices Civils de Lyon (HCL) - Centre Hospitalier Lyon-Sud
    Pierre-Bénite, Auvergne-Rhône-Alpes 69495, France
  • Institut Paoli Calmettes - Hôpital de jour
    Marseille, Bouches-du-Rhône 13273, France
  • Hopital Saint-Andre - Service d'Oncologie Medicale
    Bordeaux, Gironde 33075, France
  • Hopital Foch
    Suresnes, Hauts-de-Seine 92151, France
  • CHU Michallon - Hopital Nord - Cancérologie Et Hématologie
    Grenoble, Isère 38043, France
  • Hôpital privé Le Bois
    Lille, Nord 59000, France
  • Centre Hospitalier de Poitiers
    Poitiers, Poitou-Charentes 86021, France
  • Centre Leon Berard - departement d'oncologie medicale
    Lyon, Rhône 69373, France
  • Clinique Victor Hugo - Hematologie
    Le Mans, Sarthe 72000, France
  • CHD Vendee La Roche sur Yon - Gastro-Entérologie
    La Roche-sur-Yon, 85925, France
  • Centre de Lutte Contre le Cancer (CLCC)
    Nice, 06189, France
  • ICO - Site Rene Gauducheau - Oncologie Medicale
    Saint-Herblain, 44805, France
  • Hopital Trousseau - medical oncology
    Tours, 37044, France
  • Institut de Cancérologie de Lorraine
    Vandœuvre-lès-Nancy, 54511, France
  • Centre de Lutte Contre le Cancer (CLCC) - Gustave Roussy (Institut de Cancerologie Gustave-Roussy)
    Villejuif, Île-de-France Region 94805, France
  • Universitätsklinikum Heidelberg
    Heidelberg, Baden-Wurttemberg 69120, Germany
  • Medizinische Hochschule Hannover
    Hanover, Lower Saxony 30625, Germany
  • Ospedale S.Donato, AUSL 8 di Arezzo
    Arezzo, Arezzo 52100, Italy
  • Azienda Mater Domini
    Catanzaro, Catanzaro 88100, Italy
  • P.O. Ss. Annunziata
    Chieti Scalo, Chieti 66013, Italy
  • IRST
    Meldola (Fc), Forli 47014, Italy
  • European Institute of Oncology
    Milan, Milano 20141, Italy
  • IRCCS Policlinico San Matteo
    Pavia, Pavia 27100, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli
    Roma, Roma '00168, Italy
  • AO S.Camillo-Forlanini
    Roma, Roma 00152, Italy
  • Azienda Ospedaliera Santa Maria di Terni
    Terni, Terni 05100, Italy
  • PO di Cremona, ASST di Cremona - Oncologia medica
    Cremona, Italy
  • AOUC Azienda Ospedaliero-Universitaria Careggi
    Florence, 50134, Italy
  • IRCCS Fondazione "Giovanni Pas
    Naples, 80131, Italy
  • Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
    Tlalpan, 14080, Mexico
  • Szpital Kliniczny Przemienienia Panskiego UM w Poznaniu
    Poznan, Greater Poland Voivodeship 60-569, Poland

Showing the first 100 of 139 sites across 16 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Choueiri TK, Albiges L, Barthelemy P, Iacovelli R, Emambux S, Molina-Cerrillo J, Garmezy B, Barata P, Basu A, Bourlon MT, Moon H, Ratta R, McKay RR, Chehrazi-Raffle A, Hammers H, Heng DYC, Braendle E, Beckermann KE, McGregor BA, Motzer RJ. Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study. Lancet. 2024 Oct 5;404(10460):1309-1320. doi: 10.1016/S0140-6736(24)01758-6. Epub 2024 Sep 13. PubMed 39284329 ↗
  • Yang Y, Psutka SP, Parikh AB, Li M, Collier K, Miah A, Mori SV, Hinkley M, Tykodi SS, Hall E, Thompson JA, Yin M. Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma. Cancer Med. 2022 Aug;11(16):3106-3114. doi: 10.1002/cam4.4679. Epub 2022 Mar 18. PubMed 35304832 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Jan 2026, 52 months.

Of 35 industry-sponsored phase 3 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 59. This study's 52 months is close to that.

Counting every sponsor, half of 61 studies reached it within 56 months; a quarter within 42 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2021
First posted
Aug 3, 2021
StartActual
Sep 9, 2021
Primary completionActual
Jan 20, 2026
CompletionActual
Jan 20, 2026
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04987203
Collaborators
Parexel, Bristol-Myers Squibb
Responsible party
Sponsor
First posted
Aug 3, 2021
Start date
Sep 9, 2021
Primary completion
Jan 20, 2026
Completion
Jan 20, 2026
Last update
May 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tivozanib · Nivolumab

Start the discussion